硫酸依替米星治疗350例细菌性感染的临床研究  

Clinical study of etimicin in the treatment of bacterial infections

作　　者：陈雪华[1] 何礼贤[1] 胡必杰[1] 

机构地区：[1]上海医科大学中山医院,上海200032

出　　处：《中国抗生素杂志》2000年第B05期6-10,23,共6页Chinese Journal of Antibiotics

摘　　要：为进一步研究国产硫酸依替米星的安全性和临床疗效 ,在上海市组织 11家医院共 35 0例病例进行了 期临床实验 ,研究采用多中心开放式非对照试验设计 ,硫酸依替米星剂量为 2 0 0～ 30 0 mg/ d,1次或 2次静脉滴注 ,疗程 5～ 14d。研究表明依替米星治疗感染性疾病 ,有效率为 87.7% ,痊愈率为 5 2 .7% ,其中治疗下呼吸道感染的有效率为 88.3% ,痊愈率为 49.0 %。 32 2例病例共分离出菌株 2 73株 ,细菌学清除率为90 .1% ,体外抗菌作用表明依替米星对肠杆菌科的敏感性为 91.2 % ,高于奈替米星和庆大霉素。不良反应率为 3.43% ,且反应轻微 ,停药或对症处理后即恢复正常。说明依替米星是一个高效、安全、具有广泛临床应用价值的抗菌药物 ,值得推广。The clinial efficacy and safety of etimicin in the treatment of bacterial infections is evaluated. 350 cases were involved in the open clinical study, the dosage of each day was 200~300mg for 5~14 days. Results showed that the overall efficacy rate of etimicin were 87.7%, and the eradication rate was 90.1% respectively. The incidence of adverse events of etimicin were 3.43%, and usually the adverse events were mild and need not any treatment. It was concluded that etimicin is a highly effectively and safe broad spectrum antibacterial agent for the treatment of infection diseases.

关 键 词：硫酸依替米星 细菌性感染 药物疗法 安全性 

分 类 号：R515.05[医药卫生—内科学] R978.12[医药卫生—临床医学]